Verification of the mechanism of action of dexmedetomidine in treatment of cerebral ischemia-reperfusion injury based on network pharmacology,molecular docking,and gene chip analysis
Objective To analyze the mechanism of dexmedetomidine in treatment of cerebral ischemia-reperfusion injury based on bioinformatics,and to identify the hub genes by molecular docking and gene expression omnibus(GEO)chip verification.Methods PubChem and GeneCards were used to screen the intersection targets of dexmedetomidine and cerebral ischemia-reperfusion injury,establish a PPI network to determine hub genes,and perform GO and KEGG enrichment analysis.Finally,the Hub genes were verified by molecular docking and GEO chip data.Results There were 43 intersection targets between dexmedetomidine and cerebral ischemia-reperfusion injury.PPI screening obtained a topological network with 41 nodes and 103 edges,and the Hub genes were HTR2A,OPRM1,DRD2,SLC6A4,GRM5,CYP2C19,SLC6A3,NR3C1,and GSK3β.GO and KEGG analysis showed that dexmedetomidine intervention of cerebral ischemia-reperfusion injury involved 254 biological functions and 58 signaling pathways.Molecular docking verified that the hub genes had good affinity,and GSE23160 chip verified that DRD2,GSK3β,and NR3C1 were different(P<0.05).Conclusions Based on network pharmacology,molecular docking,and gene chip,this study found that dexmedetomidine intervention of cerebral ischemia-reperfusion injury through multi-targets,multi-biological functions and multi-pathways,verified that DRD2,GSK3β,and NR3C1 may be the hub genes,predicted key diagnostic genes and potential therapeutic genes,and laid a solid foundation for further research.
NETL
NSTL
万方数据
